Record VC Invested in Orphan Drug/Rare Disease Startups
December 15, 2014
VCs and pharma giants are pushing resources into early stage opportunities because, as is the case in quite a few other industries, a near-monopoly in a niche space is better than fierce competition in a larger market. After poring through PitchBook news coverage and valuations of the most valuable rare disease startups, a few key factors emerge as to why the rare disease space could be lucrative:
1. Potential market: With genome sequencing rapidly becoming cheaper, the number of those diagnosed with rare diseases (as well as the number of diseases) has only proliferated.